Chinese Journal of Blood Purification

Chinese Journal of Blood Purification ›› 2022, Vol. 21 ›› Issue (07): 525-529.doi: 10.3969/j.issn.1671-4091.2022.07.014

Previous Articles     Next Articles

Renin-angiotensin-aldosterone inhibitor and hyperkalemia in patients with maintenance hemodialysis

  

  1. Department of Nephrology, The Second Affiliated Hospital of  Shantou University Medical College, Guangdong 515041, China; 2Department of Nephrology, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangdong 510655, China
  • Received:2022-01-04 Revised:2022-04-15 Online:2022-07-12 Published:2022-07-12

PDF

485

Abstract: Renin-angiotensin-aldosterone inhibitor (RASi) plays an important role in lowering blood pressure and maintaining cardiac and renal function, but it also blocks the secretion of aldosterone and causes hyperkalemia. Given that RASi may lead to elevated serum creatinine and hyperkalemia in patients with chronic kidney disease (CKD) whose glomerular filtration rate has decreased, there are concerns about the use of such drugs in patients with nondialysis stage CKD 4-5. For people on maintenance hemodialysis (MHD), the safety of RASi is controversial due to the presence of factors (such as diet, clearance, medication, etc.) that affect the blood potassium of patients with MHD and the possible interaction between many factors.

Key words: Hemodialysis, Hyperkalemia, Renin-angiotensin-aldosterone inhibitor

CLC Number: